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Drug-resistant TBBackground: The tuberculosis and infections caused by nontuberculous mycobacterial
(NTM) species are increasing in patients presented with respiratory illness, and it is crucial
to document the epidemiology of these infections.
Objectives: To study the mycobacterial species and in vitro drug susceptibility trends of
Mycobacterium tuberculosis found in the respiratory specimens.
Materials and methods: A prospective descriptive study from July 2009 to December 2012.
The BACTEC MGIT system tubes with growth were used in the study. GenoType Mycobacte-
rium (Hain Diagnostika, Nehren, Germany) assays were used to identify the mycobacteria.
The drug susceptibility testing was performed by the MGIT 960 system.
Results: A total of 1745 MGIT 960 system positive tubes were included. M. tuberculosis com-
plex (MTC) constituted 67.45% of the yield isolated, 30.83% were nontuberculous mycobac-
terial species, 0.17% were Mycobacterium bovis BCG and 1.55% were not interpretable to
species levels. Mycobacterium fortuitum (45.71%), Mycobacterium abscessus (26.21%) and Myco-
bacterium intracellulare (10.41%) were major NTM identified. The drug susceptibility study
showed that 6.88% (81/1177) of MTC were drug-resistant TB, 56 isolates were resistant to
one of the first-line anti-TB drugs, 25 isolates were found to be resistant to 2 or more
first-line anti-TB drugs, of which 19 (20.46%) were MDR-TB and one of the isolates in the
year 2011 was confirmed XDR-TB.
Conclusion: M. tuberculosis, M. fortuitum, M. abscessus and M. intracellulare were major myco-
bacterial species detected in the respiratory samples. The drug susceptibility testing
showed that the majority of MTC were sensitive to first-line anti-TB drugs.
 2014 Asian-African Society for Mycobacteriology. Published by Elsevier Ltd. All rights
reserved.Introduction
Mycobacterium is a genus of Actinobacteria in the family
Mycobacteriaceae. For diagnostic and treatment purposes, the
mycobacteria can be broadly divided into: Mycobacterium
tuberculosis complex (MTC), which can cause tuberculosis(TB); Mycobacterium leprae which causes leprosy, and nontu-
berculous mycobacteria (NTM).
M. tuberculosis is a species of M. tuberculosis complex that
causes TB. TB is one of the world’s deadliest diseases with
over 9 million people becoming sick, and about 2 million
TB-related deaths worldwide have been reported [1]. In 2009,
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9.3 million new cases, and 1.8 million deaths, mostly in
developing countries [2]. However, the TB incidence rates
are falling globally; by 2012, the TB mortality rate had been
reduced by 45% since 1990 [3].
TB is a communicable disease; it spreads by respiratory
droplets from a person with an active disease which are then
inhaled by another person. The diagnosis can only be made
by demonstrating the presence of tubercle bacilli in the spu-
tum by means of microscopy and/or culture in the laboratory.
Direct microscopy is a simple, inexpensive, and reliable
technique for the detection of cases of pulmonary tuberculo-
sis. However, it has poor sensitivity in extra-pulmonary tuber-
culosis, and it cannot distinguish viable from nonviable
organisms and different mycobacterial species. It has been
reported that between 5000 and 10,000 tubercle bacilli per
milliliter of sputum is required to give a positive result.
Conventional culture by solid Lo¨wenstein–Jensen (LJ) med-
ium for mycobacterial growth is slow, requiring a 3–8 week
period of incubation. Most of the laboratories are using a fully
automated mycobacterial liquid culture BD BACTEC MGIT 960
System for rapid detection of mycobacterial growth and to
increase overall mycobacterial recovery from clinical
specimens. Culture still remains the gold standard, and every
attempt should be made to isolate the organism from speci-
mens received.
Traditionally, the mycobacterial isolates are identified to
the species level by a series of phenotypic and biochemical
tests. These tests are slow and the interpretation of results
may vary; the molecular biology techniques based on the
PCR and reverse hybridization procedure are therefore the
preferred methods in the mycobacterial identification. Sev-
eral commercial systems using various technologies for the
detection and identification of Mycobacterium spp. are in rou-
tine use, including DNA hybridization-based AccuProbe M.
tuberculosis complex (MTBC) assay (TB AccuProbe; Gen-Probe,
Inc., San Diego, Calif.) based on species-specific DNA probes,
the INNO-LiPA MYCOBACTERIA line probe assay (Innogenet-
ics, Ghent, Belgium) based on the nucleotide differences in
the 16S-23S rRNA spacer region, GenoType Mycobacterium
(Hain Diagnostika, Nehren, Germany) based on DNA hybrid-
ization technology on nitrocellulose strips, the Cobas Ampli-
cor PCR system (Roche Molecular Diagnostics, Basel,
Switzerland), and the GEN-PROBE AMPLIFIED M. tuberculosis
Direct (MTD) Test (Gen-Probe Inc., San Diego, Calif.) based
on transcription-mediated amplification and the hybridiza-
tion protection assay to qualitatively detect M. tuberculosis
ribosomal ribonucleic acid. Most of these systems can be used
to identify mycobacteria directly from positive BACTEC, MGIT
liquid cultures bottles or from the cultures [4,5].
The current TB diagnostic algorithm in the Mycobacteriol-
ogy Laboratory, University Malaya Medical Centre included
fluorescence microscopy using auramine–rhodamine stain,
culture by both BACTEC MGIT liquid culture and solid Lo¨wen-
stein–Jensen medium. The growth in the MGIT broth was
identified by molecular line probe assays. The BACTEC MGIT
960 system for in vitro drug susceptibility testing for mycobac-
teria (SIRE) was used to determine the susceptibility patterns
of four commonly used first-line anti-tuberculous drugs –
streptomycin, isoniazid, rifampicin and ethambutol – andseven second-line anti-tuberculous drugs – amikacin, capreo-
mycin, kanamycin, ofloxacin, ciprofloxacin, ethionamide and
para-amino salicylic acid.
The objective of this study was to identify the mycobacte-
rial species found in the respiratory specimens for a better
understanding of the epidemiology of the mycobacterial dis-
eases. Only the first MGIT liquid culture tube of each patient
was included in the analysis; the subsequent repeated exam-
inations were excluded in this study. The mycobacterial
species found to be positive in BACTEC MGIT liquid culture
were identified using GenoType Mycobacterium assays (Hain
Diagnostika, Nehren, Germany) and in vitro drug susceptibility
testing were carried out using the BACTEC MGIT 960 system.Materials and methods
A prospective descriptive study took place from July 2009 to
December 2012, and 1745 MGIT system tubes with growth
detected by the instrument were included in the study. On
the day of detection of growth in the MGIT 960 instrument,
a 0.1 mL aliquot of the MGIT broth was removed and exam-
ined with a Ziehl-Neelsen stain to confirm the presence of
acid-fast bacteria (AFB) and a gram-stain to ascertain there
was no contamination with bacteria. After the confirmation
of AFB, 1 ml aliquot of the MGIT broth was transferred to a
screw-capped 1 mL tube for GenoType Mycobacterium assays
(Hain Diagnostika, Nehren, Germany). The tube was first
centrifuged at 15,000g for 15 min. The supernatant was dis-
carded; the pellet was re-suspended with 100 ll of ultra-pure
distilled water. The tube was vortexed and placed in a heating
block for 30 min. The tube was then centrifuged at 15,000g for
5 min; 5 ll of the supernatant was re-suspended in 35 ll of
PNM reagent. The DNA extraction, amplification, and hybrid-
ization of the PCR products to the strips, detection and inter-
pretation of the results were performed according to the
manufacturer’s instructions. All the procedures were carried
out in the BSL 3 laboratory.
The GenoType CMwas first used to identify themycobacte-
rial species (Mycobacterium avium subspecies, Mycobacterium
chelonae, Mycobacterium abscessus, Mycobacterium fortuitum,
Mycobacterium gordonae,Mycobacterium intracellulare,Mycobacte-
rium scrofulaceum, Mycobacterium interjectum, Mycobacterium
kansasii, Mycobacterium malmoense, Mycobacterium marinum–
Mycobacterium ulcerans,Mycobacterium peregrinum, theM. tuber-
culosis complex, and Mycobacterium xenopi) isolated in the
Mycobacteriology laboratory. If the assay failed to identify
the AFB of the MGIT system tubes, the GenoType AS was
used to probe a series of additional NTM (Mycobacterium simiae,
Mycobacterium mucogenicum, Mycobacterium goodie, Mycobacte-
rium cellatum, Mycobacterium smegmatis, Mycobacterium
genavense,Mycobacterium lentiflavum,Mycobacteriumheckeshorn-
ense,Mycobacterium szulgai,Mycobacterium phlei,Mycobacterium
hemophilum, M. kansasii, M. ulcerans, Mycobacterium gastri,
Mycobacterium asiaticum, and Mycobacterium shimoidei) not
covered in the GenoType CM. GenoTypeMTBCwas used to fur-
ther characterize the M. tuberculosis complex (Mycobacterium
africanum, BCG, Mycobacterium bovis subspecies bovis, M. bovis
subspecies caprae, Mycobacterium microti and M. tuberculosis)
identified among children below 5 years of age.
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MGIT 960 system. AllM. tuberculosiswas tested for susceptibil-
ity to the four first-line drugs with critical concentration of
streptomycin (Stret) 1.0 microg/ml, isoniazid (Inh) 0.1 microg/
ml, rifampicin (Rif) 1.0 microg/ml, and ethambutol (Etham)
5.0 microg/ml as recommended by the manufacturer. The
isolates resistant to single first-line anti-TB drugs or both iso-
niazid and rifampicinwere tested for seven second-line drugs;
the critical concentrations were amikacin 1.0 microg/ml, cap-
reomycin 2.5 microg/ml, kanamycin 2.5 microg/ml, ofloxacin
2.0 microg/ml, ciprofloxacin 1.0 microg/ml, ethionamide
5.0 microg/ml and para-amino salicylic acid 4.0 microg/ml.
Results
A total of 1,745 MGIT 960 system positive tubes were included
in this study. M. tuberculosis complex was the major mycobac-
terial species identified in the positive growth MGIT tubes. It
constituted 67.45% (1177) of all the mycobacteria isolated in
this study. Nontuberculous mycobacterial species made up
30.83% (538), 3 (0.17%) of the isolates were identified as M.
bovis BCG. Twenty-seven isolates (1.55%) were not interpret-
able and were reported as mycobacterial species.
Seventeen species of nontuberculous mycobacteria were
identified among the 538 isolates. M. fortuitum (45.71%), M.
abscessus (26.21%), M. intracellulare (10.41%), M. mucogenicum
(4.28%), M. avium (2.60%) and Mycobacterium kansaii (2.42%)
were the major species identified (Table 1).
The drug susceptibility study of 1177 MTC indicated that
drug resistant TB was not high among the patients with
tuberculosis. The majority (93.12%) of the MTC were suscepti-
ble to all four first-line drugs tested. Only 81 (6.88%) MTC were
found to be drug-resistant TB. The drug-resistant TB detectedTable 1 – Mycobacterial species isolated from respiratory specim
Mycobacterial species 2009 2010
M. tuberculosis complex 168 192
Nontuberculous mycobacteria
M. fortuitum 19 29
M. abscessus 15 15
M. intracellulare 7 13
M. mucogenicum 0 0
M. avium 5 1
M. kansaii 1 0
M. chelonae 2 3
M. gordonae 2 0
M. scrofulaceum 0 2
M. interjectum 0 0
M. smegmatis 0 0
M. szulgai 0 0
M. goodii 0 0
M. genavense 0 0
M. celatum 0 0
M. lentiflavum 0 0
M. peregrinum 0 0
M. bovis BCG 0 0
Mycobacterial species 6 0
Totalfrom 2009 to 2012 was 10.72%, 5.20%, 7.28% and 5.86%, respec-
tively (Table 2). Among the drug-resistant TB, 69.14% (56 iso-
lates) were resistant to one of the first-line anti-TB drugs:
isoniazid, rifampin, ethambutol, or streptomycin and 30.86%
(25 isolates) were found to be resistant to two or more first-
line anti-TB drugs (Table 2). Mono-resistant to Isoniazid was
detected in 44.64% of mono-drug resistant TB; this was
followed by ethambutol (33.93%), rifampin (10.72%) and strep-
tomycin (10.72%). Among the MTC resistant to two or more
first-line anti-TB drugs, 6 (24.00%) were not MDR-TB (three
were resistant to streptomycin & ethambutol and three were
resistant to streptomycin and isoniazid), 19 (76.00%) were
MDR-TB and 1 of the isolates in the year 2011 was a confirmed
case of XDR-TB. Among the 19 MDR-TB, 8 were resistant to
isoniazid and rifampicin; 6 were resistant to isoniazid,
rifampicin and streptomycin; 4 were resistant to isoniazid,
rifampicin and ethambutol, and 1 was resistant to all the
first-line drugs (Table 2). Thirteen (68.42%) of the MDR-TB
cases were sensitive to all the second-line anti-TB drugs
tested, 2 (10.53%) were resistant to single second-line anti-
TB drugs, and 3 (15.79%) were resistant to 2 or more second-
line anti-TB drugs. The single MDR-TB isolate that showed
resistant to all the second-line anti-TB drugs was confirmed
to be the first XDR-TB detected by the laboratory (Table 3).
Discussions
Tuberculosis remains a leading cause of morbidity and
mortality in developing countries. Similarly, from the global
perspective, the infections caused by NTM are increasing [6]
even though the epidemiology of nontuberculous mycobacte-
rial infection in patients presented with respiratory illness
remains poorly documented [7]. NTM are widely distributedens: 2009–2012.
2011 2012 Total (%)
357 460 1177(67.45)
538(30.83)
102 96 246(45.71)
53 58 141(26.21)
16 20 56(10.41)
7 16 23(4.28)
2 6 14(2.60)
6 6 13(2.42)
2 2 9(1.67)
0 5 7(1.30)
2 3 7(1.30)
1 5 6(1.12)
3 2 5(0.93)
0 3 3(0.56)
1 1 2(0.37)
0 2 2(0.37)
0 2 2(0.37)
0 1 1(0.19)
0 1 1(0.19)
3 0 3(0.17)
11 10 27(1.55)
1745
Table 2 – Anti-TB drug susceptibility testing of MTC.
Anti-TB drug resistant patterns 2009 2010 2011 2012 Total (%)
Normal M. tuberculosis 150 182 331 433 1096(93.12)
Drug resistant M. tuberculosis 18 10 26 27 81(6.88)
Monodrug-resistant 56(69.14)
Strept 2 3 0 1 6(10.72)
Inh 4 1 5 15 25(44.64)
Rif 1 0 1 4 6(10.72)
Etham 3 0 10 6 19(33.93)
Polydrug-resistant 25(30.86)
Strept + Etham 3 0 0 0 3(12.00)
Strept + Inh 1 2 0 0 3(12.00)
Inh + Rif 4 1 3 0 8(32.00)
Inh + Rif + Strept 0 3 3 0 6(24.00)
Inh + Rif + Etham 0 0 3 1 4(16.00)
Inh + Rif + Etham + Strept 0 0 1 0 1(4.00)
Table 3 – Second-line anti-TB drug susceptibility testing of MDR-TB.
Second-line anti-TB drugs Year Total
ETN AN CAP KANA OFLO CIP PAS 2009 2010 2011 2012
S S S S S S S 4 2 6 1 13
R S S S S S S 1 1
S S R S S S S 1 1
R S S S S R S 1 1
S S S S S R R 1 1
R R S R S S S 1 1
R R R R R R R 1 1
Total 4 4 10 1 19
ETN, ethionamide; AN, amikacin; CAP, capreomycin; KANA, kanamycin; OFLO, ofloxacin; CIP, ciprofloxacin; PAS, para-amino salicylic acid.
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rates of NTM from the soil, natural and treated water are
remarkably similar in diverse geographic areas, but M. kans-
asii, M. xenopi, and M. simiae are recovered almost exclusively
from municipal water sources and rarely from other environ-
mental sources [8,9]. Because of NTM omnipresence in the
environment and there is no evidence of human-to-human
transmission [10], the isolation of NTM from the respiratory
samples does not, per se, indicate infection or clinical signif-
icance. As this study is impeded by the lack of clinical infor-
mation from patients, theprimary focus was on the studying
of the epidemiology and diversity of the mycobacterial spe-
cies inclusive of anti-TB drug susceptibility patterns of M.
tuberculosis isolated from the respiratory specimens.
NTM diseases have been reported in most industrialized
countries [11]. Currently, much of the epidemiological data
of pulmonary NTM disease come from industrialized coun-
tries, mainly Europe, North America, Australia and Japan
[12]. The lack of epidemiological data from the developing
countries could be due to the lack of laboratorymethods capa-
ble of identifying nontuberculous mycobacterial species. The
availability of commercial reverse hybridization assay (Geno-
Type Mycobacteria assays, Hain Lifescience) offers an unprec-
edented opportunity to many laboratories to identify at least
30 different nontuberculous mycobacterial species, and this
will make possible for many laboratories to identify themyco-
bacterial isolates to species levels. M. avium, M. intracellulare,M. malmoense and M. kansasii have been recognized as impor-
tant opportunistic pathogens in patients with human immu-
nodeficiency virus infection; it is important to differentiate
between M. tuberculosis complex species and NTM, as this
would allow clinicians to make decisions on optimum drug
therapy and implementation of appropriate infection control
measures in the hospitals.
M. avium complex (MAC) was the most common NTM spe-
cies causing pulmonary disease in most series of reports; in
other NTMs, such as M. abscessus, M. scrofulaceum, M. kansasii
and M. xenopi, the frequency of isolation appeared to be sim-
ilar in most industrial countries [11]. Won-Jung et al. [13]
reported that M. avium complex (n = 94, 48%) and M. abscessus
(n = 64, 33%) were 2 nontuberculous mycobacterial species
isolated from respiratory specimens in South Korea. Simons
et al. [12] reported that M. avium complex was the most fre-
quently isolated NTM species based on a literature search of
articles published about NTM species isolated from pulmon-
ary samples from persons in 20 countries in Asia during the
period March 2009–December 2009. The second most fre-
quently isolated species in the region was rapidly growing
mycobacteria (M. fortuitum complex,M. abscessus, M. chelonae);
other NTM species also frequently isolated were M. kansasii
and M. gordonae. They also reported that rapidly growing
mycobacteria were identified more frequently in pulmonary
samples from Taiwan, China and Singapore, while M. malmo-
ense and M. xenopi were reported only in India. Haverkort [14]
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cases per 100,000 population, the most common group of
mycobacteria isolated from respiratory specimens wasM. avi-
um complex, and other NTMs frequently isolated include the
rapidly growing mycobacteria M. fortuitum–M. abscessus–M.
chelonae group. In a similar report, Haverkort also highlighted
the geographical differences, notably the predominance of M.
haemophilum from Western Australia, and M. ulcerans from
Victoria and Queensland.
The present study demonstrated the high frequency of iso-
lating rapidly growing mycobacteria from the respiratory
specimens which is inconsistent with global reports [12,14].
The most common rapidly growing mycobacteria isolated in
this study was M. fortuitum (244/537, 45.4%), followed by M.
abscessus (142/537, 26.4%). Most studies indicated that MAC
is the most frequently isolated species in the respiratory sam-
ples. MAC is an acid-fast atypical mycobacterium that
belongs to group III in the Runyon classification of nontuber-
culous mycobacteria. It is primarily a pulmonary pathogen
that affects individuals who are immunocompromised (e.g.,
from AIDS, hairy cell leukemia, immunosuppressive chemo-
therapy) and occurs rarely in immunocompetent hosts [15].
In this study,M aviummade up only 2.61% andM. intracellulare
(10.4%); the figures are significantly lower as compared with
reports by many investigators. M. malmoense and M. xenopi-
mycobacterial species regularly encountered in Canada,
England and northwestern Europe [16] but uncommon in
Asia–were not identified among the NTM isolated in this
study.
Among all the NTM identifiable by GenoType assays, all
have been reported as human pathogens. Although the Geno-
Type assay was able to identify about 30 different species of
NTM, there were 27 isolates not interpretable suggesting that
additional molecular assays are needed to study the diversity
of mycobacterial species present in the environment. The
detection ofM. bovis BCG in the respiratory samples indicated
the importance of differentiating this isolate to NTM andMTC
in the laboratory, especially in young children with pulmon-
ary or disseminated mycobacterial infections.
The emergence and spread of multi-drug resistant tuber-
culosis (MDR-TB) is a worldwide problem threatening to
destabilize global tuberculosis control. The prevalence of
MDRTB is increasing throughout the world; the proportion
of multidrug resistance among the newly diagnosed TB and
previously treated cases reported between 2007 and 2010 ran-
ged from 0% to 28.9% and 0% to 65.1%, and the proportion of
MDR-TB cases with extensively drug resistance (XDR-TB)
between 2007 and 2010 was 9.4% [17]. WHO Tuberculosis Con-
trol in the SEA Region 2012 [18] reported that among the SEA
Region member countries, the MDR-TB rate is estimated to be
at around 17% (range: 17–18%) among previously treated
cases; among newly detected cases, MDR-TB incidence rates
are lower (1.7–2.5%). These incidence rates translate to
105,000 MDR-TB cases (85,000–125,000), accounting for nearly
one fourth of the world’s MDR-TB cases that were estimated
to exist among notified cases in 2010. The estimated MDR-
TB rates were highest in Thailand (34.5% among previously
treated cases) and Bangladesh (28% among previously treated
cases). Bhutan, DPR-Korea, Indonesia, Maldives, Timor-Leste
had similar rates (17% among previously treated cases),followed by India (15% among previously treated cases), Nepal
(11.7% among previously treated cases), Myanmar (10%
among previously treated cases) and Sri-Lanka (1.6% among
previously treated cases). Unfortunately, the MDR-TB inci-
dence rate in Malaysia was not cited in the report. The data
of the present study showed that 4.76% (56/1177) of the iso-
lates were mono-drug resistant TB, while 2.13% (25/1177)
were poly-drug resistant TB in which 19 (1.62%) were MDR-
TB and 1 confirmed XDR-TB. The figures were significantly
lower as comparedwith the study of Azura et al. [19] reporting
mono-drug resistant M. tuberculosis isolates of 32.65%, 14.29%
poly drug resistant and 8.16% of MDR-TB.
Mono-drug resistant TB to rifampicin is an emerging prob-
lem, particularly in patients with TB-HIV co-infections [20].
Although rifampicin is associated with the lowest occurrence
of naturally occurring resistant mutations as compared with
isoniazid [21], many of the rifampicin mono-resistant TB
cases were also resistant to isoniazid and hence rifampicin
resistance is frequently used as a proxy for multidrug-resis-
tant TB (MDR-TB) [22]. In this study, 44.64% of the mono-resis-
tant MTC were resistant to iisoniazid, 33.93% to ethambutol
and only 10.72% were resistant to rifampicin and streptomy-
cin, respectively. Mukinda et al. [23] reported that rifampicin
mono-resistant-TB cases in South Africa more than tripled,
from 31 cases in 2004 to 98 cases in 2008 with a calculated
doubling time of 1.63 cases per year. In this study, there was
no significant increase of rifampicin mono-resistant MTC.
In conclusion, M. tuberculosis remains the leading myco-
bacterial species isolated from respiratory specimens. From
the laboratory perspective, NTM are important in patients
with respiratory illness; they constitute about 32.55% of the
mycobacterial species identified in this study. Although the
majority of NTM could be identified to species levels, addi-
tional molecular assays are needed to identify and speciate
NTM not interpretable by the current Haine GenoType assays.
The rate of drug-resistant TB is low; continuing the monitor-
ing of the drug-resistant isolates at the laboratory could
provide a better treatment modality for the patients and help
in monitoring the emergence of MDR-TB and XDR-TB in the
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